LadRx Corporation Share · US2328286081 (OTC) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of LadRx Corporation
No Price
Company Profile for LadRx Corporation Share
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Company Data
Name LadRx Corporation
Company LadRx Corporation
Website
https://www.cytrx.com
Primary Exchange 
UTC
UTC
ISIN US2328286081
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Steven Kriegsman
Country United States of America
Currency USD
Employees 0,0 T
Address 11726 San Vicente Blvd Ste 650, 90049 Los Angeles
IPO Date 1986-11-10
Dividends from 'LadRx Corporation'
| Ex-Date | Dividend per Share |
|---|---|
| 07.03.2008 | 0,29 USD |
Stock Splits
| Date | Split |
|---|---|
| 01.11.2017 | 1:6 |
| 16.05.2012 | 1:7 |
| 07.03.2008 | 1250:1077 |
| 06.02.1996 | 1:4 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | CYTR |
More Shares
Investors who hold LadRx Corporation also have the following shares in their portfolio:
